Neuropsychological rehabilitation in mild and moderate Alzheimer's disease patients.
OBJECTIVE
The purpose of this study was to analyze the effect of a neuropsychological rehabilitation (NR) program on patients with Alzheimer's disease (AD).


METHODS
The sample was composed of 16 elderly outpatients who participated in an open trial with rivastigmine (6 to 12 mg/day) for 4 months and were randomized to 3 different groups: 1. group NR (N=5), 2. individualized NR (N=6) and 3. NR at home under supervision of a relative or caregiver (N=5). All 3 groups fulfilled the same NR protocol consisting of a once a week session. Just before and after the 22 week period of rehabilitation, all patients were evaluated using psychiatric and functional scales, and neuropsychological tests by interviewers that did not participate in the cognitive training.


RESULTS
The intervention did not produce any statistically significant change, but small gains were observed on some cognition tests, activities of daily living (ADL), and psychiatric symptoms in groups 1 and 2.


CONCLUSIONS
Group NR is recommended for reducing psychiatric symptoms, and individualized NR for improving ADL. NR at home either has no associated benefits, or the training sessions were not appropriately conducted by the caregiver. However, additional research with larger samples is necessary to confirm these observations.
Avila
Renata
R
Old Age Research Group (PROTER), Department and Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil. avilarenata@uol.com.br
Carvalho
Isabel A M
IA
Bottino
Cássio M C
CM
Miotto
Eliane C
EC
D000203:Activities of Daily Living; D000368:Aged; D000544:Alzheimer Disease / Q000523:psychology / Q000534:rehabilitation*; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000628:therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D048448:Phenylcarbamates / Q000627:therapeutic use*; D000068836:Rivastigmine; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014706:Verbal Learning
D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine